Clinical Edge Journal Scan

Identifying factors associated with AD severity


 

Key clinical point: Age, sex, body mass index (BMI), onset age of atopic dermatitis (AD), smoking habits, presence of palmar hyperlinearity, and other atopic diseases determine the disease severity in patients with AD.

Major finding: Compared with patients with mild AD, those with severe AD were usually older ( P = .020) and male ( P = .002) with an early onset age of AD (<2 years; P = .004), higher BMI ( P < .000), history of smoking ( P = .012), concomitant asthma ( P = .001), palmar hyperlinearity ( P = .013), hand dermatitis ( P = .020), history of contact allergy ( P = .042), and higher immunoglobulin E levels ( P < .0001).

Study details: Findings are from a single-center, cross-sectional observational study including 502 Finnish patients with AD, of which 146, 231, and 125 patients had mild, moderate, and severe AD, respectively.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Salava A et al. Factors associated with severity of atopic dermatitis - a Finnish cross-sectional study. J Eur Acad Dermatol Venereol. 2022 (Jun 29). Doi: 10.1111/jdv.18378

Recommended Reading

European survey finds wide variations in the use of phototherapy for atopic eczema
MDedge Dermatology
Eczema causes substantial burden for many infants and preschoolers
MDedge Dermatology
Methotrexate’s impact on COVID-19 vaccination: New insights made
MDedge Dermatology
‘I shall harm’
MDedge Dermatology
Multi-dimensional and heterogeneous nature of disease burden in atopic dermatitis
MDedge Dermatology
Adolescents and children with moderate-to-severe atopic dermatitis benefit from dupilumab
MDedge Dermatology
Moderate-to-severe atopic dermatitis: Abrocitinib improves clinical scores in IGA nonresponders
MDedge Dermatology
Atopic dermatitis: Improvement in disease severity and skin barrier function with dupilumab
MDedge Dermatology
Atopic dermatitis: Upadacitinib-induced acne does not pose a significant safety risk
MDedge Dermatology
Difamilast shows promise as long-term therapeutic option for atopic dermatitis
MDedge Dermatology